<< MedPlexus announces creation of “Cash for Clunkers” program | Discovery of possible genetic link between environmental toxins and bone disease in multiple myeloma >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Ελληνικά | Русский | Svenska | Polski

HIV/AIDS funding, treatment standards, empowering women addressed at ICAAP

Published on August 13, 2009 at 9:11 PM · No Comments

Funding to fight the spread of HIV/AIDS in Asia and the Pacific has fallen short of the demand, and the majority of available money has missed reaching those at highest risk -- Swarup Sarkar, director of Asia unit for the Global Fund to Fight AIDS, Tuberculosis and Malaria -- said during a session at the 9th International Congress on AIDS in Asia and the Pacific (ICAAP) in Bali, Indonesia, the Jakarta Post reports.

 "More than 80 percent of the available budget has gone to low-risk young people, compared with less than 20 percent that has gone to high-risk young people," he said (Maulia, 8/13).

In a related story, the Phnom Penh Post examines the conflict between changing the existing HIV treatment guidelines for "resource limited settings" and the funds needed to provide universal HIV treatment – a topic discussed at the ICAAP meeting (Green, 8/13).

IBNS/thaindian.com examines the recent release and ICAAP session on the book, "Diamonds," which tells the stories of 11 HIV-positive women living in the Asia-Pacific region. The book, sponsored by UNIFEM, East Asia, and UNAIDS, emphasizes the role HIV-positive women can play in the fight against HIV/AIDS (Biswas, 8/13). A second IBNS/thaindian.com story examines new techniques are being used by advocates to help empower HIV-positive women (Biswas [2], 8/13). In a separate story, IBNS/thaindian.com examines the role men can play in helping to protect women from HIV/AIDS (Biswas [3], 8/13).

Reuters examines the disruption of the ICAAP meeting Wednesday when a "small band of protestors" lashed out at the pharmaceutical company Roche, which they argue prices its Hepatitis C medication "too high for dying [HIV-positive] patients to afford" (Lyn, 8/12).

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading